Min.Order / FOB Price:Get Latest Price
50 Gram |
FOB Price:USD 2030.0000 -2050.0000 |
475207-59-1 Sorafenib tosylate anti-tumor drug
Sorafenib tosylate is a novel multi-target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking the RAF/MEK/ERK-mediated cell signaling pathway, and also inhibits VEGF and platelet-derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
Product name | Sorafenib tosylate |
CAS | 475207-59-1 |
Synonyms | SORAFENIB TOSYLATE;Sorafenib & its intermediates;Sorafinib mesylate;4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate;Sorafenib Tosylate(Bay 43-9006,Nexavar);2-PyridinecarboxaMide, 4-[4-[[[[4-chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-N-Methyl-, 4-Methylbenzenesulfonate;Sorafenib Tosylate (Nexavar);Sorafenib (Nexavar) |
Molecular formula | C28H24ClF3N4O6S |
Molecular weight | 637.0265696 |
Mol File | 475207-59-1.mol |
Appearance | White powder |
EINECS number | 641-758-8 |
Application | API |
Used as a pharmaceutical intermediates.
It is used for the treatment of advanced liver cancer.
Sorafenib Tosylate (Bay 43-9006, Nexavar) is a small molecular inhibitor of VEGFR, PDGFR, c-Raf and B-Raf with IC50s of 18 nM, 10 nM, 3 nM and 15 nM, respectively.
Sorafenib Tosylate (Bay 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively
CAS NO:51446-62-9
CAS NO:62-31-7
CAS NO:53-86-1
CAS NO:2530-83-8
CAS NO:75980-60-8
CAS NO:540737-29-9
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View